Skip to main content
Terug
Watch Compare

Matinas BioPharma Holdings, Inc.

Datakwaliteit: 83%
MTNB
NYSE Manufacturing Chemicals
€ 0,54
▲ € 0,01 (1,13%)
6 months return
—
Momentum
Neutral
ROE
-146,37%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-146,37%
Onder sectorgemiddelde (-54,47%)
ROIC-61,64%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,78
Interest CoverageN/A

Waardering

PE (TTM)
-0,32
Boven sectorgemiddelde (-1,50)
P/B Ratio0,51
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -7,01 M

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstverassingen

EPS
Reported Estimate
Q22024 Q32024 Q42024
Reported -€ 0,02 -€ 0,85 -€ 0,81
Estimate -€ 1,00 -€ 1,06 -€ 0,78
Verrassing +98,00% +19,43% -3,28%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -146,37% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -10,35 M
ROE -146,37% ROA -97,97%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -7,01 M
ROIC -61,64% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,78
Debt / Equity N/A Current Ratio 3,78
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,16 M Tangible Book Value 4,20 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,32 · EV/EBITDA: N/A
P/E Ratio -0,32 Forward P/E N/A
P/B Ratio 0,51 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -211,60%
Market Cap 3,31 M Enterprise Value -2,12 M

Per Share

EPS: -2,00 · FCF/Share: -1,09
EPS (Diluted TTM) -2,00 Revenue / Share N/A
FCF / Share -1,09 OCF / Share -1,09
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 67,77% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 67,77%
SBC-Adj. FCF -8,78 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — 1,10 M 1,10 M 3,19 M 33.333,0
Net Income -10,35 M -24,25 M -22,94 M -21,00 M -23,28 M
EPS (Diluted) -2,00 -4,98 -0,11 — —
Gross Profit — — — — —
Operating Income -6,96 M -24,59 M -23,77 M -24,59 M -24,73 M
EBITDA — — — — —
R&D Expenses 85.000,0 11,43 M 14,49 M 16,68 M 14,58 M
SG&A Expenses — — — — —
D&A 32.000,0 365.000,0 385.000,0 337.000,0 244.395,0
Interest Expense — — — — —
Income Tax -80.000,0 -80.000,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,21 M 12,64 M 25,10 M 44,82 M 61,33 M
Total Liabilities 2,38 M 5,05 M 5,86 M 8,18 M 8,83 M
Shareholders' Equity 4,83 M 7,59 M 19,25 M 36,64 M 52,49 M
Total Debt — — — — —
Cash & Equivalents 4,00 M 7,28 M 4,79 M 6,83 M 21,03 M
Current Assets 4,08 M 8,03 M 15,54 M 34,53 M 50,99 M
Current Liabilities 1,46 M 2,67 M 2,62 M 4,29 M 4,35 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 0,5 1,6
ROE % -146,4 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3